Shanghai Pharma Rare Disease Medicine

Shanghai Pharma Rare Disease Medicine, also known as SPH Ruier, is the dedicated rare disease platform of Shanghai Pharmaceuticals Holding Co., Ltd. Established in 2020, the company focuses on the research, development, and commercialization of treatments for rare diseases, covering therapeutic areas such as neurology, endocrinology, metabolism, and oncology. It manages a portfolio of over 20 varieties involving 34 rare diseases in China and maintains a robust pipeline of both innovative and generic drugs. The company operates a specialized production platform for rare disease and pediatric medicines, including China's first continuous flow production technology platform designed to reduce costs and accelerate the availability of orphan drugs.